Analysis of oligonucleotides by accurate mass LC/MS: Sequencing and impurity analysis to support development at Arrowhead Pharmaceuticals
Oligonucleotides have grown to represent an increasingly important class of therapeutic modalities. During development of new chemical entities, it is critical to both determine sequences, and identify process impurities and degradation pathways using LC/MS. These tasks are further complicated by severe data analysis challenges, requiring significant time for execution by expert level users. The main reason for these challenges is due to the lack of automation, with users often relying on manual processing with user-generated spreadsheets. Agilent BioConfirm 12.0 has been expanded to contain oligonucleotide analysis capabilities, and examples from work at Arrowhead Pharmaceuticals will be presented in this webinar, showing expedited accurate mass LC/MS analyses.
Key learning objectives
- Gain background knowledge on oligonucleotide therapeutics, focusing mostly on siRNA
- Understand the importance of structure characterization and impurity identification, as well as the current challenges with existing software platforms
- Learn from a practical demonstration about a case where LC/MS analyses have been undertaken to confirm the molecular sequence, as well as to understand process impurities and degradants
Who should attend?
- QA/QC laboratories
- Biopharma analytical development scientists
- Biopharma process development scientists
- CDMO labs
- Diagnostic development labs
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.